Publications by authors named "Trosch R"

Current clinician-rated tardive dyskinesia (TD) symptom scales have not addressed the expanding clinical signs and functional impact of TD. The study objective was to develop and test the reliability of a new integrated instrument. A movement disorder neurologist devised the outline of the rating scale.

View Article and Find Full Text PDF

In land plants and cyanobacteria, co-translational association of chlorophyll (Chl) to the nascent D1 polypeptide, a reaction center protein of photosystem II (PSII), requires a Chl binding complex consisting of a short-chain dehydrogenase (high chlorophyll fluorescence 244 [HCF244]/uncharacterized protein 39 [Ycf39]) and one-helix proteins (OHP1 and OHP2 in chloroplasts) of the light-harvesting antenna complex superfamily. Here, we show that an ohp2 mutant of the green alga Chlamydomonas (Chlamydomonas reinhardtii) fails to accumulate core PSII subunits, in particular D1 (encoded by the psbA mRNA). Extragenic suppressors arose at high frequency, suggesting the existence of another route for Chl association to PSII.

View Article and Find Full Text PDF

Photosynthesis is a central determinant of plant biomass production, but its homeostasis is increasingly challenged by heat. Little is known about the sensitive regulatory principles involved in heat acclimation that underly the biogenesis and repair of chloroplast-encoded core subunits of photosynthetic complexes. Employing time-resolved ribosome and transcript profiling together with selective ribosome proteomics, we systematically deciphered these processes in chloroplasts of Chlamydomonas reinhardtii.

View Article and Find Full Text PDF

Introduction: In patients with cervical dystonia (CD), pain is a major contributor to disability and social isolation and is often the main reason patients seek treatment. Surveys evaluating patient perceptions of their CD symptoms consistently highlight pain as a troublesome and disabling feature of their condition with significant impact on daily life and work.

Areas Covered: In this article, the authors review the epidemiology, assessment, possible mechanisms and treatment of pain in CD, including a meta-analysis of randomized controlled trial data with abobotulinumtoxinA.

View Article and Find Full Text PDF

Introduction: The efficacy and safety of abobotulinumtoxinA in the management of cervical dystonia has been established in randomized, controlled trials that use a selected trial population. In this meta-analysis of observational data, we evaluated the real-life effectiveness of abobotulinumtoxinA as delivered in routine clinical practice.

Methods: Meta-analysis of patient-level data for adult patients with cervical dystonia treated with abobotulinumtoxinA from three prospective, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349).

View Article and Find Full Text PDF

In plant cells, chloroplast gene expression is predominantly controlled through post-transcriptional regulation. Such fine-tuning is vital for precisely orchestrating protein complex assembly as for the photosynthesis machinery and for quickly responding to environmental changes. While regulation of chloroplast protein synthesis is of central importance, little is known about the degree and nature of the regulatory network, mainly due to challenges associated with the specific isolation of transient ribosome interactors.

View Article and Find Full Text PDF
Article Synopsis
  • - Cervical dystonia (CD) is a neurological disorder causing involuntary neck muscle contractions, and the study examined the long-term safety and effectiveness of abobotulinumtoxinA (aboBoNT-A) treatments in adults using a new 2-mL dilution option.
  • - In the research, 112 patients received up to three treatments of aboBoNT-A every 12-16 weeks, with evaluation criteria including treatment-emergent adverse events and the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores.
  • - Results showed a significant decrease in TWSTRS scores over treatment cycles, indicating improved symptoms, with reported side effects being mostly mild, signifying that longer-term
View Article and Find Full Text PDF
Article Synopsis
  • RimabotulinumtoxinB (RIMA) shows promise as a treatment for excessive salivation (sialorrhea) in adults with neurological disorders, potentially offering benefits over traditional oral medications.
  • A clinical trial with 187 participants assessed the safety and effectiveness of RIMA at doses of 2500 U and 3500 U compared to a placebo, measuring salivary flow reduction and patient improvement after four weeks.
  • Results indicated that both RIMA doses significantly decreased salivary flow rates compared to placebo, highlighting its potential as an effective treatment option for this condition.
View Article and Find Full Text PDF